SCHEMBL279950

SCHEMBL279950

Cc1ccc(C(=O)NCCC(=O)O)s1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.71
POLB P06746 2/20 0.71
TDP1 Q9NUW8 1/20 0.71
NPC1 O15118 5/20 0.62
RAB9A P51151 5/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
USP2 O75604 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
ALDH1A1 P00352 1/20 0.58
NAMPT P43490 2/20 0.52
LMNA P02545 1/20 0.52
DAO P14920 1/20 0.52
TAS1R3 Q7RTX0 1/20 0.49
TAS1R1 Q7RTX1 1/20 0.49
GAA P10253 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
MEN1 O00255 1/20 0.45
KDM4E B2RXH2 1/20 0.45
ESR1 P03372 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10708932 0.86 KMT2A (0.70) KMT2APOLBTDP1NPC1RAB9A
SCHEMBL15296736 0.85 POLB (0.59) KMT2APOLBTDP1NPC1RAB9A
SCHEMBL16523476 0.84 POLB (0.58) KMT2APOLBTDP1NPC1RAB9A
SCHEMBL12124267 0.83 POLB (0.65) KMT2APOLBTDP1NPC1RAB9A
SCHEMBL12124440 0.83 KMT2A (0.65) KMT2APOLBTDP1NPC1RAB9A
SCHEMBL280023 0.83 POLB (1.00) KMT2APOLBTDP1NPC1RAB9A
SCHEMBL277890 0.81 KMT2A (0.55) KMT2APOLBTDP1NPC1RAB9A
SCHEMBL16313561 0.81 POLB (0.63) KMT2APOLBTDP1NPC1RAB9A
SCHEMBL12313820 0.81 RAB9A (0.56) KMT2APOLBTDP1NPC1RAB9A
SCHEMBL12124465 0.80 RAB9A (0.67) KMT2APOLBTDP1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL KMT2A 3398/4885POLB 4352/4885TDP1 2969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.